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Abstract
This invited paper provides a summary of a keynote lecture delivered at the 2011 Australasian Podiatry Conference.
Gout is the most prevalent inflammatory arthropathy. It displays a striking predilection to affect the first
metatarsophalangeal joint as well as joints within the mid-foot and ankle. A number of factors are known to
reduce urate solubility and enhance nucleation of monosodium urate crystals including decreased temperature,
lower pH and physical shock, all of which may be particularly relevant to crystal deposition in the foot. An
association has also been proposed between monosodium urate crystal deposition and osteoarthritis, which also
targets the first metatarsophalangeal joint. Cadaveric, clinical and radiographic studies indicate that monosodium
urate crystals more readily deposit in osteoarthritic cartilage. Transient intra-articular hyperuricaemia and
precipitation of monosodium urate crystals is thought to follow overnight resolution of synovial effusion within the
osteoarthritic first metatarsophalangeal joint. The proclivity of gout for the first metatarsophalangeal joint is likely to
be multi-factorial in origin, arising from the unique combination of the susceptibility of the joint to osteoarthritis
and other determinants of urate solubility and crystal nucleation such as temperature and minor physical trauma
which are particularly relevant to the foot.
Background
Gout is a true crystal deposition disease in which all
clinical manifestations are considered to be directly
attributable to the presence of monosodium urate
(MSU) crystals. It is one of the most prevalent inflam-
matory arthropathies with a prevalence of approximately
1.4%, and is the most common inflammatory arthropa-
thy in men [1]. Both the prevalence and incidence of
gout appear to be rising [2]. The primary risk factor for
the development of gout is elevation of serum uric acid
(urate) levels, or hyperuricaemia. As uric acid levels rise
and exceed the physiological saturation threshold of uric
acid in body tissues, formation and deposition of MSU
crystals occurs in and around joints.
The propensity of gout for the foot was recognised by
the ancient Greeks who referred to it as podagra, lit-
erally “foot-grabber” [3]. The name “gout” derives from
humoral theory and the Latin word gutta or “drop”,
podagra being thought to arise as a result of the bodily
humours falling to the affected body part. Although our
current understanding of the pathogenesis of gout is
dramatically distant from humoral theory, these observa-
tions concerning the intimate relationship between gout
and the foot have been reinforced over the centuries
and continue today. This review will consider the ways
in which gout affects the foot and discuss potential
mechanisms underlying this relationship.
Clinical presentation of gout and involvement of
the foot
After an often prolonged period of asymptomatic hyper-
uricaemia, the initial manifestation of gout is usually an
acute attack of synovitis affecting a single peripheral
joint, most commonly the first metatarsophalangeal
joint (MTPJ). Other commonly affected joints include
the mid-tarsal joints, ankles, knees, fingers, wrists and
elbows (Figure 1). Such attacks are characterised by sud-
den onset of excruciating joint pain, typically taking less
than 24 hours from symptom onset to reach peak inten-
sity, with associated joint swelling, overlying erythema
and exquisite tenderness to touch. Although acute gout
should be treated rapidly with a non-steroidal anti-
inflammatory drug (NSAID) or colchicine, it usually
resolves completely over a period of two to three weeks
even without treatment. A variable period of time then
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any medium, provided the original work is properly cited.elapses until the patient experiences a further attack (the
“intercritical period”). With time, attacks may increase
in severity and frequency, involve different joint sites,
and may become oligo- or polyarticular. Eventually,
without treatment, the patient may develop chronic
tophaceous gout, characterised by chonic pain and stiff-
ness, joint damage and erosive arthropathy, and clini-
cally evident subcutaneous nodular deposits of MSU
crystals (tophi) which can occur at the toes, Achilles’
tendons, pre-patellar tendons, fingers, olecranon pro-
cesses, and less commonly, the ears (Figure 2).
Gout displays a striking tendency to affect the foot, in
particular the first MTPJ. The initial attack of gout
affects the first MTPJ in 56-78% of patients [4-7] and
the joint is involved at some point in the course of
disease in 59-89% [4,6,8-10]. Fewer studies report the
frequency of involvement of other joints. However,
mid-foot and ankle involvement occurs in 25-50% and
18-60% of patients respectively [5,8,9]. In contrast, the
upper limb is involved in 13-46% [4,6,8,10] and the
finger interphalangeal joints in only 6-25% [5,8,9].
Sub-clinical involvement in the foot also appears to be
common-place. MSU crystal deposits have been
observed in synovial fluid aspirated from first MTPJs
that have never been affected by an acute attack of gout
[11,12]. Furthermore, a study which examined the first
MTPJs of 39 males with gout using high resolution
ultrasonography found erosions to be present in 45% of
22 first MTPJs that had never been affected by acute
gout [13].
Gout has a number of chronic manifestations which
a r ee a s i l yr e c o g n i s a b l ea ss u c hi n c l u d i n gt o p h a c e o u s
deposits and a characteristic erosive arthropathy. How-
e v e r ,i ti sa l s oa s s o c i a t e dw i t han u m b e ro fo t h e rl e s s
specific foot problems. Perhaps not surprisingly given
the frequency of first MTPJ involvement, hallux valgus
is a common finding. In a community-based case-
control study, hallux valgus was found in 41% of gout
suffers compared to 25% of age- and gender-matched
control subjects (odds ratio (OR) 2.10, 95% confidence
interval (CI) 1.39 to 3.18, adjusted for body mass index
(BMI) and use of diuretics) [14]. Big toe pain occurring
on most days for at least a month within the last year
was reported by 16% of those with gout compared to
6% of controls (adjusted OR 2.94, 95% CI 1.62 to 5.34).
Given the striking predilection of gout for the foot,
there has been surprisingly little work examining the
influence of gout on foot function, gait and plantar pres-
sure distributions. A recent study compared functional
and biomechanical foot characteristics between 25 patients
with chronic gout and 25 age- and gender-matched con-
trol subjects with no history of gout [15]. Patients with
chronic gout were found to have slower walking velocity,
reduced step and stride length, reduced peak plantar pres-
sure under the hallux, and higher mid-foot pressure-time
integrals compared to controls. The authors postulate that
gait pattern is altered in chronic gout in an attempt to off-
load the first MTPJ thereby reducing pain. Further studies
are necessary to explore these observations in more detail
and examine the contribution of chronic pain in the great
toe, hallux valgus, obesity and osteoarthritis (OA) to gait
patterns in patients with gout.
Factors influencing crystal deposition
Gout is one of the best understood inflammatory arthro-
pathies. Clinical features can be easily understood and
interpreted in the context of a clearly elucidated patho-
genetic process. Specific ris kf a c t o r ss u c ha sg e n e t i c s ,
dietary factors, co-morbidity and its treatment lead to
Figure 1 Distribution of joints typically affected by gout
(reproduced with the permission of the author and the Royal
College of General Practitioners: Roddy E, Doherty M. Gout. In:
RCGP Guide to MSK Disorders in Primary Care. Ed: Warburton L (in
press)).
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occurs [16,17]. Crystals are then shed into the joint and
activate the inflammatory cascade via the NALP3
inflammasome [18,19]. Hence, any explanation of why
gout targets the foot must link these pathological pro-
cesses to the specific anatomical, functional, and disease
characteristics of the foot (Figure 3).
Temperature
As described above, gout tends to affect distal peripheral
joints, not only in the foot but also in the upper limb,
with central axial joints such as the shoulders, hips and
spine only rarely affected. The solubility of urate
decreases with reducing temperature [20,21] enhancing
nucleation of MSU crystals, that is, the “birth” of new
crystals. Reduced solubility of urate at lower tempera-
tures has therefore been suggested to account for the
o c c u r r e n c eo fg o u ta tc o o l e rd i s t a lj o i n t ss u c ha st h e
foot-ankle complex. However, this theory does not
a c c o u n tf o rt h ep r e f e r e n c eo fg o u tf o rt h ef i r s tM T P J
ahead of the great toe interphalangeal (IP) joint or the
lesser MTPJs.
Trauma and pH
A further well-recognised clinical feature of gout is the
tendency of an acute attack to be precipitated by physical
trauma such as stubbing the toe or following physical
activity. Enhanced MSU crystal nucleation has been
reported in vitro following mechanical agitation of solu-
tions supersaturated with sodium urate [22]. The same
authors demonstrated that nucleation is also potentiated
by both acidification and addition of calcium ions. Lower-
ing of pH has a direct action on MSU crystal nucleation
but also enhances nucleation by increasing calcium ion
activity. Whilst their observations concerning mechanical
agitation provide evidence that a physical shock can
directly lead to MSU crystal nucleation, the authors
hypothesised that local trauma indirectly enhances crystal
nucleation by lowering synovial pH [22]. Hence, the sus-
ceptibility of the foot to physical trauma might also help
to explain the predilection of gout for the foot.
Cartilage damage and osteoarthritis
More recently, the deposition of MSU and calcium pyr-
ophosphate dihydrate (CPPD) crystals in areas of
Figure 2 Tophaceous gout affecting the right great toe and finger interphalangeal joints. Note the asymmetrical swelling and yellow-
white discolouration.
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which examined 7855 adult human tali from 4007
donors [23]. Crystal deposits, both MSU and CPPD,
were an uncommon finding, being present in specimens
from only 5% of donors. However, where seen, crystal
deposits were usually found within or adjacent to a car-
tilage lesion. Only 8% of tali with crystal deposits had
no gross evidence of cartilage degeneration. Cartilage
lesions tended to be located at sites of biomechanical
stress such as the articulation of the margin of the tro-
chlea with the tibia or fibula or where apposition with
anterior tibial osteophytes was thought to have
occurred. In a separate study, the epitaxial nucleation
and growth of MSU crystals was observed to occur on
fragments of articular cartilage [24]. Thus there appears
to be a relationship between cartilage lesions and the
anatomical location of MSU crystal deposition.
In support of these observations, clinical and radio-
graphic evidence exists of an association between gout
and OA. Several case reports and small case series
describe the occurrence of acute attacks of gout and/or
tophi at first MTPJs and finger distal interphalangeal
(DIP) joints also affected by OA [25-30]. A Polish hos-
pital-based study of 262 patients with gout found an
association of gout and radiographic OA at the first
MTPJs, tarsal joints and knees [31]. A more recent
study of 164 patients with gout recruited from primary
care found a very strong association between joints that
had previously been the site of an acute attack of gout
and evidence of OA on clinical examination (OR 7.94,
95%CI 6.27 to 10.05, adjusted for age, gender, BMI and
diuretic use) [8]. Significant associations were seen
between acute attacks of gout and the presence of clini-
c a lO Aa tt h ef i r s tM T P J s ,m i d - f o o t ,k n e ea n df i n g e r
DIP joints.
Why are gout and osteoarthritis associated?
The observations outlined above that MSU crystals tend
to deposit at sites of cartilage damage and that clinical
and radiographic evidence exists of an association
between gout and OA lead to the important question of
the mechanism by which gout and OA might be asso-
ciated. There are three possible explanations for this
association.
Hyperuricaemia
MSU crystal formation 
and deposition
“Shedding” of crystals 
into the joint space
Acute inflammation 
“podagra”
Lower 
temperature
Physical 
stress/trauma
First MTPJ osteoarthritis
• Increased chondroitin sulphate 
concentration
• Degradation of  protein-polysaccharide 
complexes
• Epitaxial nucleation and growth of MSU
crystals on cartilage fragments
• Transient increases in synovial fluid 
urate concentration in resolving effusions
Lower pH
Increased calcium 
ion activity
Figure 3 Processes enhancing MSU crystal formation and deposition at the first MTPJ.
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states of gout and nodal generalised OA? These two
conditions share the common risk factor of obesity
[32,33]. In a related study to the primary care study
described above [8], generalized nodal OA, defined as
the presence of Heberden’s or Bouchard’s nodes on at
least two digits in each hand [34], was no more com-
monplace in subjects with gout than age-and gender-
matched community controls but, as discussed above,
hallux valgus and self-reported knee and big toe pain
were more frequent in those with gout [14]. Although
this case-control study was underpowered, these find-
ings do not suggest that an association exists between
the disease states of gout and generalised OA.
T h es e c o n da n dt h i r de x p l a nations are related and
concern the hypothesis that the association of gout and
OA occurs at local joint sites and relates to the co-loca-
tion of MSU crystal deposits and cartilage lesions. Speci-
fically, they question the direction of this association,
namely, does the presence of osteoarthritic cartilage pre-
dispose to the local formation and deposition of MSU
crystals or do MSU crystals themselves initiate and pro-
gress cartilage damage? Evidence to support the deposi-
tion of MSU crystals in osteoarthritic cartilage rather
than MSU crystals leading to cartilage damage arises
from two sources. Although the primary care study
described above was cross-sectional, making it difficult
to infer causality, the strength of the association
between involvement of gout and OA at individual joint
sites did not increase with longer duration of gout [8].
A further insight into the direction of association
between MSU crystal deposition and OA is provided by
a recent study which examined the relationship between
synovial fluid uric acid levels and the radiographic sever-
i t yo fk n e eO A[ 3 5 ] .A l t h o u g hs y n o v i a lf l u i du r i ca c i d
was found to correlate with baseline knee OA severity,
it was not associated with change in OA severity over 3
years. These two observations do not suggest that the
association between the occurrence of gout and OA at
individual joint sites is due to MSU crystal-initiated
joint damage. Furthermore, certain properties of the
osteoarthritic joint are thought to influence urate solubi-
lity and predispose to local MSU crystal disposition [36].
Increased concentrations of chondroitin sulphate and
degradation of protein-polysaccharide complexes found
within articular cartilage have been shown to reduce
urate solubility and lead to the precipitation and growth
o fM S Uc r y s t a l s[ 3 7 - 3 9 ] .H o w e v e r ,i ti sa l s op o s s i b l e
that the association between MSU crystal deposition
and OA is bi-directional whereby existing osteoarthritic
change predisposes to local formation and deposition of
MSU crystals which then initiate further cartilage
damage.
Why does gout target the first
metatarsophalangeal joint?
The studies discussed above provide clear evidence of an
association between MSU crystal deposition and OA.
Whilst further studies are required to definitively answer
the questions of direction of association and causality, it
appears that MSU crystals more readily deposit in
osteoarthritic cartilage and that the presence of OA
influences the distribution of joints affected by gout.
However, OA cannot solely explain the typical distribu-
tion of joints affected by gout, as many joints commonly
affected by OA such as the knees, finger IP joints, and
hips are less frequently affected by gout than the first
MTPJ, and other target joints for gout such as the
ankle, wrist and elbow are infrequent sites for primary
OA. Is it plausible therefore that the relationship
between MSU crystal deposition and OA is of more
relevance for the first MTPJ than other joint sites?
The first MTPJ is certainly targeted by OA although
foot OA is under-studied in comparison to other com-
monly affected sites such as the hand and knee. A
recent systematic review of population-based epidemio-
logical studies found that the estimated prevalence of
r a d i o g r a p h i cO Aa tt h ef i r s tM T P Jm a yb ea sh i g ha s
39% in middle-aged to older adults [40]. Simkin pro-
posed a model to explain the clinical observations that
acute attacks of gout are commonly precipitated by phy-
sical stress and occur overnight, based upon the co-
occurrence of gout and OA at the first MTPJ [41]. In
this model, a synovial effusion develops in an osteoar-
thritic first MTPJ during the day and subsequently
resolves when the joint is rested overnight. Synovium is
more permeable to water than urate and hence, as the
effusion resolves, water leaves the joint more rapidly
than urate. This results in a transient increase in the
synovial fluid urate concentration which leads to preci-
pitation of MSU crystals if the saturation threshold of
urate is exceeded. As discussed above, MSU crystal for-
mation and deposition will be further potentiated in the
osteoarthritic first MTPJ by impaired urate solubility
and enhanced crystal nucleation arising from factors
relating to the anatomical location of the first MTPJ
namely lower distal temperature and physical stress
[20-22], and those relating to OA namely increased con-
centrations of chondroitin sulphate, degradation of pro-
tein-polysaccharide complexes, and epitaxial MSU
crystal nucleation and growth on cartilage fragments
[24,37-39] (Figure 3).
Conclusion
The striking predilection of gout for the first MTPJ
appears to be multi-factorial in origin and arises from
the unique combination of the susceptibility of the joint
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ture, minor physical trauma and biomechanical stress,
leading to ideal conditions for MSU crystal formation
and deposition in predisposed hyperuricaemic indivi-
duals, manifesting as clinical gout.
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